Literature DB >> 20976853

Local recurrence of hepatocellular carcinoma after radiofrequency ablation.

Wang-Jun Liao1, Min Shi, Jin-Zhang Chen, Ai-Min Li.   

Abstract

A 51-year-old Chinese male with a 20-year history of hepatitis B was diagnosed with hepatocellular carcinoma in the right anterior portion of the liver, sized 3.5 cm × 3.2 cm, and was treated with radiofrequency ablation (RFA) on December 18, 2001. The patient did not receive antiviral therapy for hepatitis B virus after RFA. The treated lesion reduced gradually and reached its minimum size of 1.7 cm × 1.5 cm seven years later on November 18, 2008. However computed tomography findings revealed that a recurrence lesion of 6.0 cm × 4.8 cm which was histologically confirmed overlapped the previous treated lesion at the 8th year on December 3, 2009. Although recurrence at 8 years after curative RFA is a rare event, such a possibility must be kept in mind. To find and treat the recurrence lesion promptly, long-term and close monitoring is warranted after RFA. Meanwhile, the recurrence-prevention therapy is as important as close monitoring for those patients with a history of hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20976853      PMCID: PMC2965293          DOI: 10.3748/wjg.v16.i40.5135

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function.

Authors:  Sung Noh Hong; Sun-Young Lee; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Jong Chul Rhee; Dongil Choi; Hyo Keun Lim; Kwang-Woong Lee; Jae Won Joh
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

3.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

4.  Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  Hideo Yoshida; Haruhiko Yoshida; Eriko Goto; Takahisa Sato; Takamasa Ohki; Ryota Masuzaki; Ryosuke Tateishi; Tadashi Goto; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Hepatol Int       Date:  2007-09-26       Impact factor: 6.047

Review 5.  Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients.

Authors:  Toru Ishikawa
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

6.  Therapeutic effectiveness of echo-guided percutaneous radiofrequency ablation therapy with a LeVeen needle electrode in hepatocellular carcinoma.

Authors:  Luigi Solmi; Giovanni Nigro; Enrico Roda
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

7.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan.

Authors:  Masatoshi Makuuchi; Norihiro Kokudo; Shigeki Arii; Shunji Futagawa; Shuichi Kaneko; Seiji Kawasaki; Yutaka Matsuyama; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Yukihisa Saida; Tadatoshi Takayama; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2008-01       Impact factor: 4.288

9.  Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

Authors:  Man-Fung Yuen; Wai-Kay Seto; Danny Hoi-Fan Chow; Kit Tsui; Danny Ka-Ho Wong; Vincent Wing-Shun Ngai; Benjamin Chun-Yu Wong; James Fung; John Chi-Hang Yuen; Ching-Lung Lai
Journal:  Antivir Ther       Date:  2007

10.  Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.

Authors:  M E Mendy; T Welzel; O A Lesi; P Hainaut; A J Hall; M H Kuniholm; S McConkey; J J Goedert; S Kaye; S Rowland-Jones; H Whittle; G D Kirk
Journal:  J Viral Hepat       Date:  2009-10-27       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.